Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer

Sponsor
Haihong Yang, MD, Pricipal investigator
Study ID
NCT02054052
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Bevacizumab 100 mg, intrapleural injection treating MPE after the drainage of MPE

Study Details

Malignant pleural or pericardial effusion is common in lung cancer, and intrapleural drugs injection is important in the treatment. Non- cytotoxic drugs include those with a sclerosing effect that produces pleurodesis, which is easy to cause severe chest pain despite of no influence on the following chemotherapy. Tumor angiogenesis is important in producing MPE. Bevacizumab has been administrated locally in treating optic nerve sickness successfully by anti-VEGF mechanism. So we hypothesize that intrapleural bevacizumab is also effective in treating MPE.

Key Dates

First listed
Feb 4, 2014
Start date
Jan 31, 2014
Status verified
Mar 2019
Primary completion
Mar 31, 2019
Completion
Mar 31, 2019

Study Design

Enrollment
22 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab
    Bevacizumab 100 mg, intrapleural injection treating maliganant pleural or percardial effusion

Primary Outcome Measure

Lung cancer symptom [ Time Frame: Evaluated by lung cancer symptom scale 21-30 days after the treatment ]

Related Studies